Clinical Reviews in Allergy & Immunology

, Volume 34, Issue 1, pp 111–117

Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia

  • Dario Roccatello
  • Simone Baldovino
  • Daniela Rossi
  • Osvaldo Giachino
  • Morteza Mansouri
  • Carla Naretto
  • Debora Di Simone
  • Simona Francica
  • Roberto Cavallo
  • Mirella Alpa
  • Franca Napoli
  • Luigi M. Sena
Article

DOI: 10.1007/s12016-007-8019-0

Cite this article as:
Roccatello, D., Baldovino, S., Rossi, D. et al. Clinic Rev Allerg Immunol (2008) 34: 111. doi:10.1007/s12016-007-8019-0
  • 171 Views

Abstract

Type II mixed cryoglobulinemia (MC) is a systemic vasculitis, associated in most cases with hepatitis C virus (HCV) infection, sustained by proliferation of oligoclonal cells. Systemic B cell depletion and clinical remission can be achieved in non-Hodgkin lymphoma by human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen (rituximab). Similar effects could be expected in type II MC. Twelve patients, mean age 61.9 years (range 37–76), 11 with HCV infection genotype 2a2c (4 cases) or 1b (6 cases) and 3 (1 case) and symptomatic type II MC with systemic manifestations, including renal involvement, marrow clonal restriction, large necrotizing ulcers, and polyneuropathy, were considered eligible for rituximab therapy because of resistance or intolerance to conventional therapy or important bone marrow infiltration. Rituximab was administered intravenously at a dose of 375 mg/m2 on days 1, 8, 15, and 22. Two more doses were administered 1 and 2 months later. No other immunosuppressive drugs were added. Response was evaluated by assessing the changes in clinical signs, symptoms, and laboratory parameters. Levels of proteinuria, hematuria, erythrocyte sedimentation rate, cryocrit, rheumatoid factor, and IgM decreased while C4 values increased and HCV viral load remained stable during short- and medium-term observation. Bone marrow abnormalities were found to reverse to normal. Constitutional symptoms disappeared or ameliorated. No acute or delayed side effects were seen. Based on this experience and a number of reports published in the last 5 years, Rituximab appears to be a safe and effective therapeutic option in symptomatic patients with HCV-associated MC with signs of systemic vasculitis.

Keywords

Mixed cryoglobulinemiaCryoglobulinemic glomerulonephritisRituximabAnti CD20 monoclonal antibodyCryoglobulinsHCV syndrome

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Dario Roccatello
    • 1
  • Simone Baldovino
    • 2
  • Daniela Rossi
    • 1
  • Osvaldo Giachino
    • 1
  • Morteza Mansouri
    • 2
  • Carla Naretto
    • 1
  • Debora Di Simone
    • 2
  • Simona Francica
    • 2
  • Roberto Cavallo
    • 1
  • Mirella Alpa
    • 1
  • Franca Napoli
    • 2
  • Luigi M. Sena
    • 2
  1. 1.Centro Multidisciplinare di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Struttura Complessa a Direzione Universitaria di Immunologia Clinica (CMID), Ospedale S.G. BoscoTorinoItaly
  2. 2.Dipartimento di Medicina e Oncologia Sperimentale, Sezione di Patologia GeneraleUniversità di TorinoTorinoItaly